

CONTRAINDICATIONS

NOT FOR INJECTION BY USUAL PARENTERAL ROUTES.

Do not use in patients with anuria.

WARNINGS

FOR UROLOGIC IRRIGATION ONLY.

Solutions for urologic irrigation must be used with caution in patients with severe cardiopulmonary or renal dysfunction.

Irrigating fluids used during transurethral prostatectomy have been demonstrated to enter the systemic circulation in relatively large volumes; thus, sorbitol-mannitol irrigant must be regarded as a systemic drug. Absorption of large amounts of fluids containing sorbitol-mannitol and the osmotic diuresis it produces may significantly alter cardiopulmonary and renal dynamics.

Hyperglycemia from metabolism of sorbitol may occur in patients with diabetes mellitus.

Hyperlactatemia from metabolism of sorbitol may potentially produce a significant lactic acidemia in metabolically compromised patients.

The contents of an opened container should be used promptly to minimize the possibility of bacterial growth or pyrogen formation.

Discard the unused portion of irrigation solution since it contains no preservatives. Do not heat over 66°C (150°F).

PRECAUTIONS

Cardiovascular status, especially of the patient with cardiac disease, should be carefully observed before and during transurethral resection of the prostate when using Sorbitol-Mannitol Irrigation, because the quantity of fluid absorbed into the systemic circulation by opened prostatic veins may produce significant expansion of the extracellular fluid and lead to fulminating congestive heart failure.

Shift of sodium-free intracellular fluid into the extracellular compartment following systemic absorption of solution may lower serum sodium concentration and aggravate pre-existing hyponatremia.

Excessive loss of water and electrolytes may lead to serious imbalances. With continuous irrigation, loss of water may occur in excess of electrolytes, producing hypernatremia.

Sustained diuresis that results from transurethral irrigation with Sorbitol-Mannitol Irrigation may obscure and intensify inadequate hydration or hypovolemia.

Aseptic technique is essential for the use of sterile solutions for irrigation. The administration set should be attached promptly. Unused portions should be discarded and a fresh container of appropriate size used for the start-up of each cycle or repeat procedure.

Do not administer unless solution is clear, seal is intact and container is undamaged.

Discard unused portion.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Studies with Sorbitol-Mannitol Irrigation have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.

Nursing Mothers: Caution should be exercised when Sorbitol-Mannitol Irrigation is administered to a nursing woman.

Pregnancy: Teratogenic Effects.

Pregnancy Category C. Animal reproduction studies have not been conducted with Sorbitol-Mannitol Irrigation. It is also not known whether Sorbitol-Mannitol Irrigation can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sorbitol-Mannitol Irrigation should be given to a pregnant woman only if clearly needed.

Pediatric Use: The safety and effectiveness of Sorbitol-Mannitol Irrigation have not been established. Its limited use in pediatric patients has been inadequate to fully define proper dosage and limitations for use.

ADVERSE REACTIONS

Adverse reactions may result from intravascular absorption of sorbitol and mannitol. The literature reports occasional adverse reactions from intravenous sorbitol-mannitol infusions. Consequences of absorption of urologic irrigating solutions include fluid and electrolyte disturbances such as acidosis, electrolyte loss, marked diuresis, urinary retention, edema, dryness of mouth, thirst and dehydration; cardiovascular disorders such as hypotension, tachycardia, angina-like pains; pulmonary disorders such as pulmonary congestion; and other general reactions such as blurred vision, convulsions, nausea, vomiting, diarrhea, rhinitis, chills, vertigo, backache and urticaria. Allergic reactions from sorbitol-mannitol have also been reported.

Should any adverse reaction occur, discontinue the irrigant, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

OVERDOSAGE

In the event of dehydration, fluid or solute overload, discontinue the irrigation, evaluate the patient and institute corrective measures as indicated. (See ***WARNINGS, PRECAUTIONS*** and ***ADVERSE REACTIONS***.)

DOSAGE AND ADMINISTRATION

Sorbitol-Mannitol Irrigation should be administered only by transurethral instillation with appropriate urologic instrumentation. A disposable administration set should be used. The total volume of solution used for irrigation is solely at the discretion of the surgeon.

Height of container(s) above the operating table in excess of 60 cm (approx. 2 ft) has been reported to increase intravascular absorption of the irrigating fluid.

Parenteral drug products should be inspected visually for particulate matter and

discoloration prior to administration, whenever container and solution permit. (See **PRECAUTIONS.**)

HOW SUPPLIED

Sorbitol-Mannitol Irrigation is supplied in single-dose 3000 mL flexible irrigation container (NDC No. 0409-7981-08 / 0990-7981-08).

ICU Medical is transitioning NDC codes from the "0409" to a "0990" labeler code. Both NDC codes are expected to be in the market for a period of time.

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing.

Revised: July, 2018

EN-4664

ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

PRINCIPAL DISPLAY PANEL - 3000 mL Bag Label

3000 mL
NDC 0990-7981-08

SORBITOL-
MANNITOL
IRRIGATION

EACH 100 mL CONTAINS
SORBITOL 2.70 g; MANNITOL
0.54 g. pH 5.2 (4.0 TO 7.0)
178 mOsmol/LITER (CALC.)
STERILE, NONPYROGENIC.

INDICATIONS:
FOR UROLOGIC IRRIGATION.

CONTRAINDICATIONS:
NOT FOR INJECTION. USE ONLY
IF SOLUTION IS CLEAR AND
CONTAINER IS UNDAMAGED.

WARNINGS:
DO NOT HEAT OVER 66°C (150°F)
OR STORE ABOVE 40°C (104°F).
SINGLE-DOSE CONTAINER.
CONTAINS NO BACTERIOSTAT.
DISCARD UNUSED PORTION.
USE ASEPTIC TECHNIQUE.

USUAL DOSAGE:
SEE INSERT.

RX ONLY

IM-4383

3

V

CONTAINS DEHP

ICU Medical, Inc.,
Lake Forest, Illinois, 60045, USA

icumedical

3000 mL



NDC 0990-7981-08

SORBITOL- MANNITOL IRRIGATION

EACH 100 mL CONTAINS
SORBITOL 2.70 g; MANNITOL
0.54 g. pH 5.2 (4.0 TO 7.0)
178 mOsmol/LITER (CALC.)
STERILE, NONPYROGENIC.

INDICATIONS:
FOR UROLOGIC IRRIGATION.

CONTRAINDICATIONS:
NOT FOR INJECTION. USE ONLY
IF SOLUTION IS CLEAR AND
CONTAINER IS UNDAMAGED.

WARNINGS:
DO NOT HEAT OVER 66°C (150°F)
OR STORE ABOVE 40°C (104°F).
SINGLE-DOSE CONTAINER.
CONTAINS NO BACTERIOSTAT.
DISCARD UNUSED PORTION.
USE ASEPTIC TECHNIQUE.

USUAL DOSAGE:
SEE INSERT

SEE INSERT.

RX ONLY



IM-4383



CONTAINS DEHP

250 —



ICU Medical, Inc.,
Lake Forest, Illinois, 60045, USA

icumedical

PRINCIPAL DISPLAY PANEL - Overwrap Label

2
HDPE

TO OPEN TEAR AT NOTCH

DO NOT REMOVE FROM OVERWRAP UNTIL READY FOR USE. AFTER REMOVING THE OVERWRAP, CHECK FOR MINUTE LEAKS BY SQUEEZING CONTAINER FIRMLY. IF LEAKS ARE FOUND, DISCARD SOLUTION AS STERILITY MAY BE IMPAIRED. RECOMMENDED STORAGE: ROOM TEMPERATURE (25°C). AVOID EXCESSIVE HEAT. PROTECT FROM FREEZING. SEE INSERT.
98-4321-R14-3/98

TO OPEN TEAR AT NOTCH



HDPE

DO NOT REMOVE FROM OVERWRAP UNTIL READY FOR USE. AFTER REMOVING THE OVERWRAP, CHECK FOR MINUTE LEAKS BY SQUEEZING CONTAINER FIRMLY. IF LEAKS ARE FOUND, DISCARD SOLUTION AS STERILITY MAY BE IMPAIRED. RECOMMENDED STORAGE: ROOM TEMPERATURE (25°C). AVOID EXCESSIVE HEAT. PROTECT FROM FREEZING. SEE INSERT.
98-4321-R14-3/98

SORBITOL-MANNITOL

sorbitol and mannitol irrigant

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0990-7981
Route of Administration	URETHRAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
SORBITOL (UNII: 506T60A25R) (SORBITOL - UNII:506T60A25R)	SORBITOL	2.7 g in 100 mL

MANNITOL (UNII: 3OWL53L36A) (MANNITOL - UNII:3OWL53L36A)

MANNITOL

0.54 g in 100 mL

Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0990-7981-08	4 in 1 CASE	10/01/2019	
1		1 in 1 POUCH		
1		3000 mL in 1 BAG; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA018316	10/01/2019	

Labeler - ICU Medical Inc. (118380146)

Establishment

Name	Address	ID/FEI	Business Operations
Hospira, Inc.		827731089	ANALYSIS(0990-7981)

Revised: 10/2025

ICU Medical Inc.